Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Document › Details

Pieris Pharmaceuticals, Inc.. (11/9/16). "Press Release: Pieris Pharmaceuticals Reports Financial Results and Provides Corporate Update for the Third Quarter Ended September 30, 2016". Boston, MA.

Organisations Organisation Pieris Pharmaceuticals Inc. (Nasdaq: PIRS)
  Group Pieris (Group)
  Organisation 2 Daiichi Sankyo Co., Ltd. (TSE: 4568.JP)
  Group Daiichi Sankyo (Group)
Products Product PRS-080 (Anticalin hepcidin antagonist)
  Product 2 PRS-343 (CD137/HEr2 bispecfic anticalin-based drug, Pieris)
Person Person Yoder, Stephen S. (Steve) (Pieris 201001– CEO before MorphoSys Head Licensing + IP)
     


   
Record changed: 2021-06-10

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for Pieris (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2021 Time to Register 650x300




» top